Get the Stockscreener App
39.75
0.15%
-0.06
After Hours:
39.76
0.010
+0.03%
Centessa Pharmaceuticals Plc Adr stock is traded at $39.75, with a volume of 706.30K.
It is down -0.15% in the last 24 hours and up +0.71% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
See More
Previous Close:
$39.81
Open:
$39.78
24h Volume:
706.30K
Relative Volume:
0.28
Market Cap:
$6.15B
Revenue:
$15.06M
Net Income/Loss:
$-250.69M
P/E Ratio:
-22.40
EPS:
-1.7748
Net Cash Flow:
$-209.28M
1W Performance:
+0.40%
1M Performance:
+0.71%
6M Performance:
+42.07%
1Y Performance:
+214.98%
1-Day Range:
$39.70
$39.78
1-Week Range:
$39.57
$39.85
52-Week Range:
$10.95
$40.26
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
39.75 | 6.16B | 15.06M | -250.69M | -209.28M | -1.7748 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Downgrade | Truist | Buy → Hold |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Dec-10-25 | Resumed | Oppenheimer | Outperform |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Aug-29-25 | Resumed | Oppenheimer | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| May-28-25 | Initiated | Needham | Buy |
| May-08-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-31-25 | Initiated | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
Eli Lilly, Centessa Pharmaceuticals receive US green light - MLex
HSR waiting period lapses for Centessa (CNTA) sale to Eli Lilly under UK scheme - Stock Titan
LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal - MSN
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plcCNTA - ChartMill
Centessa (NASDAQ: CNTA) to be acquired by Lilly for $38 plus up to $9 CVR - Stock Titan
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge? - Yahoo Finance
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026 - GlobeNewswire Inc.
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Centessa (NASDAQ: CNTA) schedules 2026 AGM and advisory pay vote - Stock Titan
38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Short Interest Down 47.5% in April - MarketBeat
Wells Fargo Downgrades Centessa Pharmaceuticals ADR to Equal Weight From Overweight, Adjusts Price Target to $42 From $35 - marketscreener.com
Lilly to buy Centessa (NASDAQ: CNTA) for $38/ share plus $9 CVR - Stock Titan
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Finviz
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Free cash flow per share of Centessa Pharmaceuticals PLC ADR – MUN:260 - TradingView
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Sahm
This Akamai Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Sahm
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 1-Year High – What’s Next? - Defense World
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA) - Sahm
Centessa Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CNTA) - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal - Yahoo Finance
JPMorgan Chase & Co. Sells 186,539 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):